Cartesian Therapeutics Reports Deepening Losses, $56.7M Impairment, and Halts SLE Program

summarizeSummary

Cartesian Therapeutics reported a net loss of $130.3 million for 2025, a significant increase from $77.4 million in 2024, driven by a $56.7 million impairment charge related to discontinuing its SLE program. The company's cash position of $126.9 million provides a runway for at least 12 months, supported by a 2024 private placement and a $100 million ATM program, but it faces ongoing capital needs.

check_boxKey Events

• Full-Year 2025 Financial Results

  Net loss increased to $130.3 million in 2025 from $77.4 million in 2024. Collaboration and license revenue significantly decreased to $0.4 million from $38.3 million in the prior year, primarily due to the termination of the Astellas and Genovis agreements.

• Significant Impairment Charge and Pipeline Shift

  The company recorded a $56.7 million impairment charge on its in-process research and development (IPR&D) asset for Descartes-08 in SLE, following a decision to no longer pursue development in that indication. Development of Descartes-15 was also paused to prioritize other programs.

• Liquidity and Future Funding Needs

  Cash, cash equivalents, and restricted cash stood at $126.9 million as of December 31, 2025, providing a runway for at least the next 12 months. The company completed a $130.0 million private placement in July 2024 and established a $100.0 million At-The-Market (ATM) equity offering program in December 2024, with no shares sold yet.

• Clinical Program Updates

  The Phase 3 AURORA trial for Descartes-08 in Myasthenia Gravis (MG) was initiated in May 2025 with an FDA Special Protocol Assessment (SPA) agreement. An IND for a Phase 2 trial of Descartes-08 in Myositis was accepted in December 2025, with the trial expected to commence in the first half of 2026.

auto_awesomeAnalysis

Cartesian Therapeutics' annual report reveals a challenging financial year, marked by a significant increase in net loss and a sharp decline in collaboration revenue. The company recorded a substantial $56.7 million impairment charge related to its Descartes-08 program for Systemic Lupus Erythematosus (SLE) after deciding to discontinue development in that indication. While the company has secured liquidity through a $130 million private placement in 2024 and established a $100 million ATM program, it anticipates needing substantial additional funding to support its ongoing operations and clinical programs. Positive updates include the progression of Descartes-08 into a Phase 3 trial for Myasthenia Gravis (MG) with an FDA Special Protocol Assessment (SPA) agreement, and the initiation of a Phase 2 trial for Myositis. However, the strategic decision to narrow its pipeline by halting SLE and pausing Descartes-15 development reflects a need to conserve capital and focus resources amidst significant losses.